5.14 Keratitis, Viral, Herpes Simplex

Date of last review:

19/12/2025

Date of next review:

19/12/2027

Date of publication:

19/1/2026


This is a GOS Specialist Supplementary condition and should be managed by community optometrists in line with national guidance (8). This guideline should be read in conjunction with ‘Supporting information’ guidance [link to Supporting Information page]


Differential diagnosis (1)

  • Herpes zoster keratitis

  • Bacterial, fungal, or amoebic keratitis (consider Acanthamoeba in contact lens wearers)

  • Healing epithelial defects (e.g. abrasions)

  • Other causes of pseudodendrites


Possible management by optometrist

Advice

  • Sunglasses for symptom relief (1)

  • Dendritic keratitis in a contact lens wearer may indicate Acanthamoeba infection rather than viral keratitis. Such cases require specialist assessment and should not be treated within community settings – see further management options for referral guidance (7)

  • Exclude viral retinitis following pupil dilatation (especially in immunocompromised patients - requires same-day referral) (1)

    • Signs of viral retinitis include (1):

      • Peripheral infiltrates

      • Vasculitis

      • Intra-retinal haemorrhages

      • Vitreous inflammation

  • HSK is a potentially blinding disease

    • Apply low threshold for referral (1)

Treatment

  • Acute epithelial HSK (non-contact lens wearing adults, classic dendritic ulcer)

    • Topical antivirals (1)

  • Recurrent epithelial HSK

    • Topical antivirals (1) if:

      • Clear history of recurrence

      • Diagnosis is certain

      • No stromal involvement

  • Monitor closely within first 72 hours (where appropriate (7)) to evaluate healing, but refer urgently to ophthalmology if epithelium has not healed after 7 days (1) (consult local guidance as they may vary on review timescales e.g. 7 days for first review, or 14 days for referral (7))

  • Stromal HSK:

    • The College of Optometrists Clinical Management Guideline (CMG) recommends that stromal involvement should be referred as an emergency same day referral to ophthalmology (1)

NB Some local Health Boards have specific guidance for treating HSK in the community. Local guidance can be found within the clinical and referral protocols section of their host Board page on eyes.nhs.scot (7)

NB Oral antivirals decrease the recurrence of stromal HSK by 50% when used prophylactically at low dose. There is no indication for prophylactic use for epithelial HSK, apart from for those patients with multiple recurrence (1)


Typical adult dosage/duration

(Blue text = IP, black text = non-IP)

  • Ganciclovir 0.15% eye gel (1,5) (POM): One drop 5 times daily until healing complete, then 3 times daily for a further 7 days (consult local guidance as they may vary on tapering (7)), treatment does not usually exceed 21 days (2,3)

Regimens should be adjusted according to severity and patient factors (e.g. age, weight, pregnancy, renal function). Prescribing should follow local formulary and local/national guidance where available (7).

In cases of known sensitivities, please consult local formularies for alternative options (7).


Further management options

  • GOS Specialist Supplementary Stage 1 to assess and establish presence of HSK* (8)

  • If HSK present (no stromal involvement), GOS Specialist Supplementary Stage 2* treatment should be provided by a local IP optometrist/OMP who is registered and qualified to carry out GOS Specialist Supplementary Stage 2 management; intra-referral (practice to practice) should take place to facilitate this (8)

    • Urgent referral if no healing after 7 days (1) (local guidance may vary on timescales (7))

  • Stromal involvement, children, contact lens wearers, or bilateral cases (1)

    • Consider emergency same-day referral (1,7)

  • Treatment may be provided within available locally enhanced schemes, or by community IP optometrists/OMPs, as appropriate (outwith GOS Specialist Supplementary) (7)

*Treatment should be provided in line with “Annex C of the Statement” (8) https://www.eyes.nhs.scot/for-professionals/legislation/


Possible management in secondary care or local/community pathways where available  (1,8)

  • See Further management options

  • Diagnostic confirmation via swab, PCR or viral culture (1)

  • Topical and/or systemic antivirals (e.g. aciclovir, famciclovir) reduce recurrence risk (1)

  • Topical steroids for stromal/endothelial disease (1)

  • Anti-glaucoma agents for raised IOP (1)

  • Epithelial debridement (1)

  • Corneal transplant (keratoplasty) for scarring in quiescent cases (1)


College of Optometrists Clinical Management Guideline (1) 

Herpes simplex keratitis (HSK) - College of Optometrists *

*With special thanks to The College of Optometrists for providing the evidence framework for diagnosis and management from the Clinical Management Guidelines (CMGs) for this condition. All references to the College/CMGs are included where appropriate and form the basis of the Community Eyecare Guidelines.


Guidance is informed by the following sources 

  1. College of Optometrists Clinical Management Guidelines Clinical Management Guidelines - College of Optometrists

  2. Advisory alignment with the College of Optometrists Formulary Optometrists' Formulary - College of Optometrists

  3. Advisory alignment with the BNF BNF (British National Formulary) | NICE

  4. Advisory alignment with the Summary Product Characteristics taken from the EMC Home - electronic medicines compendium (emc)

  5. Advisory alignment with Scottish Health Board formularies (where a clear majority is present) *

  6. Advisory alignment with expert consensus (CEGG), informed by sources 2-5 above

  7. Advisory alignment with expert consensus (CEGG) 

  8. “Annex C of the Statement” https://www.eyes.nhs.scot/for-professionals/legislation/

* Scottish formularies should be available within the Prescribing section of your Health Board pages on the eyes.nhs.scot website. If unavailable, contact your local Health Board for further information; Health Boards landing page

 


If you have a query relating to this page, please email NSS.ComEyecareGuidelineGroup@nhs.scot